Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results
Status:
Not yet recruiting
Trial end date:
2027-03-15
Target enrollment:
Participant gender:
Summary
This is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and
safety of selinexor in combination with azacitidine and venetoclax for untreated acute
myeloid leukemia based on MRD results on day 14 of the first cycle.